CTP13 biosimilar infliximab is comparable to reference infliximab and adalimumab in highly anticipated realworld study

PANTS study shows that CTP13 is an efficacious therapy option when investigating personalised approaches to antiTNF therapy VIENNA&8211;BUSINESS WIRE&8211;Twelvemonth data from the Personalised AntiTNF therapy in Crohns disease Study PANTS was pres...